Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BA3182 in advanced adenocarcinoma
NCT05808634Phase 1Recruiting
- Sponsor
- BioAtla
- Start
- Jul 2023
- Primary completion
- Sep 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BA3182 in Adenocarcinoma, sponsored by BioAtla. Primary endpoints: Dose Limiting Toxicity at 24 months, Maximum Tolerated Dose at 24 months and 1 more. Started Jul 2023; status: recruiting.
02
Drugs
BA3182
03
Conditions
Adenocarcinoma
Beyond the preview
Go deeper on NCT05808634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05808634.